Quince Therapeutics, Inc. (QNCX) - Cash Flow Conversion Efficiency
Based on the latest financial reports, Quince Therapeutics, Inc. (QNCX) has a cash flow conversion efficiency ratio of -0.487x as of March 2026. Cash flow conversion efficiency measures how effectively a company's net assets (equity) generate operating cash flow. It is calculated by dividing operating cash flow ($-7.63 Million) by net assets ($15.67 Million). A higher ratio indicates that the company is more efficient at using its equity to generate cash flow from its core operations. See QNCX net asset quality index to measure how much of total assets are equity-financed.
Quince Therapeutics, Inc. - Cash Flow Conversion Efficiency Trend (2017–2025)
This chart illustrates how Quince Therapeutics, Inc.'s cash flow conversion efficiency has evolved over time, based on yearly financial data. Check QNCX operating cash flow to net income to evaluate the quality of earnings relative to operating cash generation.
Quince Therapeutics, Inc. Competitors by Cash Flow Conversion Efficiency
The table below lists competitors of Quince Therapeutics, Inc. ranked by their cash flow conversion efficiency.
| Company | Cash Flow Conversion Efficiency |
|---|---|
|
nTels Co. Ltd
KQ:069410
|
-0.030x |
|
Mighty Kingdom Ltd
AU:MKL
|
-0.727x |
|
GREAT PORTLAND ESTATES PLC
LSE:GPE
|
0.002x |
|
Xilam Animation
PA:XIL
|
0.207x |
|
Burgundy Diamond Mines Ltd
AU:BDM
|
0.009x |
|
Lion Industries Corporation Bhd
KLSE:4235
|
-0.076x |
|
THUNDER GOLD CORP.
F:Z25
|
-0.045x |
|
Sasbadi Holdings Bhd
KLSE:5252
|
-0.042x |
Annual Cash Flow Conversion Efficiency for Quince Therapeutics, Inc. (2017–2025)
The table below shows the annual cash flow conversion efficiency of Quince Therapeutics, Inc. from 2017 to 2025. For the full company profile with market capitalisation and key ratios, see QNCX company net worth.
| Year | Net Assets | Operating Cash Flow | Cash Flow Conversion Efficiency | Change |
|---|---|---|---|---|
| 2025-12-31 | $-35.71 Million | $-41.42 Million | 1.160x | +209.60% |
| 2024-12-31 | $30.15 Million | $-31.90 Million | -1.058x | -392.27% |
| 2023-12-31 | $85.08 Million | $-18.29 Million | -0.215x | +50.89% |
| 2022-12-31 | $100.59 Million | $-44.04 Million | -0.438x | +17.51% |
| 2021-12-31 | $118.59 Million | $-62.93 Million | -0.531x | -79.89% |
| 2020-12-31 | $172.26 Million | $-50.82 Million | -0.295x | -2.37% |
| 2019-12-31 | $115.48 Million | $-33.28 Million | -0.288x | -75.98% |
| 2018-12-31 | $71.42 Million | $-11.70 Million | -0.164x | -133.79% |
| 2017-12-31 | $-20.28 Million | $-9.83 Million | 0.485x | -- |
About Quince Therapeutics, Inc.
Quince Therapeutics, Inc., a biotechnology company, focuses on acquiring, developing, and commercializing therapeutics for patients with debilitating and rare diseases. The company's lead asset candidature comprises eDSP, which is in Phase 3, for the treatment of rare pediatric neurodegenerative disease, including A-T, an inherited autosomal recessive neurodegenerative and immunodeficiency disord… Read more